Berlin I - Search Results

1

Smoking related diseases: the central role of monoamine oxidase.

Rendu F, Peoc'h K, Berlin I, Thomas D, Launay JM. Rendu F, et al. Among authors: berlin i. Int J Environ Res Public Health. 2011 Jan;8(1):136-47. doi: 10.3390/ijerph8010136. Epub 2011 Jan 14. Int J Environ Res Public Health. 2011. PMID: 21318020 Free PMC article. Review.

2

Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.

Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ. Berlin I, et al. Br J Clin Pharmacol. 1990 Dec;30(6):805-16. doi: 10.1111/j.1365-2125.1990.tb05445.x. Br J Clin Pharmacol. 1990. PMID: 1705137 Free PMC article. Clinical Trial.

3

A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers.

Berlin I, Saïd S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, Lecrubier Y, Puech AJ. Berlin I, et al. Clin Pharmacol Ther. 1995 Oct;58(4):444-52. doi: 10.1016/0009-9236(95)90058-6. Clin Pharmacol Ther. 1995. PMID: 7586937 Clinical Trial.

4

Monoamine oxidase A and B activities in heavy smokers.

Berlin I, Said S, Spreux-Varoquaux O, Olivares R, Launay JM, Puech AJ. Berlin I, et al. Biol Psychiatry. 1995 Dec 1;38(11):756-61. doi: 10.1016/0006-3223(95)00084-4. Biol Psychiatry. 1995. PMID: 8580230 Clinical Trial.

5

Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.

Radat F, Berlin I, Spreux-Varoquaux O, Elatki S, Ferreri M, Puech AJ. Radat F, et al. Among authors: berlin i. Psychopharmacology (Berl). 1996 Oct;127(4):370-6. doi: 10.1007/s002130050100. Psychopharmacology (Berl). 1996. PMID: 8923574 Clinical Trial.

6

Effects of past history of major depression on smoking characteristics, monoamine oxidase-A and -B activities and withdrawal symptoms in dependent smokers.

Berlin I, Spreux-Varoquaux O, Saïd S, Launay JM. Berlin I, et al. Drug Alcohol Depend. 1997 Apr 14;45(1-2):31-7. doi: 10.1016/s0376-8716(97)01338-0. Drug Alcohol Depend. 1997. PMID: 9179504 Clinical Trial.

7

Platelet monoamine oxidase B activity is inversely associated with plasma cotinine concentration.

Berlin I, Spreux-Varoquaux O, Launay JM. Berlin I, et al. Nicotine Tob Res. 2000 Aug;2(3):243-6. doi: 10.1080/14622200050147501. Nicotine Tob Res. 2000. PMID: 11082824

8

Monoamine oxidases and tobacco smoking.

Berlin I, Anthenelli RM. Berlin I, et al. Int J Neuropsychopharmacol. 2001 Mar;4(1):33-42. doi: 10.1017/S1461145701002188. Int J Neuropsychopharmacol. 2001. PMID: 11343627 Free article. Review.

9

Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation.

Berlin I, Aubin HJ, Pedarriosse AM, Rames A, Lancrenon S, Lagrue G; Lazabemide in Smoking Cessation Study Investigators. Berlin I, et al. Addiction. 2002 Oct;97(10):1347-54. doi: 10.1046/j.1360-0443.2002.00258.x. Addiction. 2002. PMID: 12359039 Clinical Trial.

10

Endocrine and metabolic effects of smoking cessation.

Berlin I. Berlin I. Curr Med Res Opin. 2009 Feb;25(2):527-34. Curr Med Res Opin. 2009. PMID: 19205076 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

397 results

Search Page